test

CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.

The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.

The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.

The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.

The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.

The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.